TORONTO--(BUSINESS WIRE)--
To my fellow Shareholders,
With our 2013-2014 fiscal year completed, I want to take a few moments to reflect on the past twelve months and to outline our plans for the year ahead. In the last year, we completed our transformation from a private, research-focused, drug-discovery venture into a publicly-traded, commercialization-focused, clinical stage drug development company. We are very proud of the support that our shareholders have given us through this transition as we work to bring new, safer drugs to market.
Help employers find you! Check out all the jobs and post your resume.